Correale, Jorge 2016. Evolutionary Thinking in Medicine.
Cvetkovic, J. Sofronic-Milosavljevic, Lj. Ilic, N. Gnjatovic, M. Nagano, I. and Gruden-Movsesijan, A. 2016. Immunomodulatory potential of particular Trichinella spiralis muscle larvae excretory–secretory components. International Journal for Parasitology, Vol. 46, Issue. 13-14, p. 833.
Maizels, R.M. 2016. Parasitic helminth infections and the control of human allergic and autoimmune disorders. Clinical Microbiology and Infection, Vol. 22, Issue. 6, p. 481.
Tanasescu, Radu 2016. Neuro-Immuno-Gastroenterology.
Bashi, Tomer Bizzaro, Giorgia Ben-Ami Shor, Dana Blank, Miri and Shoenfeld, Yehuda 2015. The mechanisms behind helminth's immunomodulation in autoimmunity. Autoimmunity Reviews, Vol. 14, Issue. 2, p. 98.
Bashi, Tomer Konikoff, Tom Blank, Miri and Shoenfeld, Yehuda 2015. Infection and Autoimmunity.
Fleming, J. O. and Weinstock, J. V. 2015. Clinical trials of helminth therapy in autoimmune diseases: rationale and findings. Parasite Immunology, Vol. 37, Issue. 6, p. 277.
Leonardi, Irina Frey, Isabelle and Rogler, Gerhard 2015. Helminth therapy for organic diseases?. Translational Research, Vol. 166, Issue. 6, p. 586.
Schmitz, Katja Barthelmes, Julia Stolz, Leonie Beyer, Susanne Diehl, Olaf and Tegeder, Irmgard 2015. “Disease modifying nutricals” for multiple sclerosis. Pharmacology & Therapeutics, Vol. 148, p. 85.
Vejzagić, Nermina Adelfio, Roberto Keiser, Jennifer Kringel, Helene Thamsborg, Stig Milan and Kapel, Christian M.O. 2015. Bacteria-induced egg hatching differs for Trichuris muris and Trichuris suis. Parasites & Vectors, Vol. 8, Issue. 1,
Voldsgaard, A Bager, P Garde, E Åkeson, P Leffers, AM Madsen, CG Kapel, C Roepstorff, A Thamsborg, SM Melbye, M Siebner, H Søndergaard, HB Sellebjerg, F and Sørensen, P Soelberg 2015. Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Multiple Sclerosis Journal, Vol. 21, Issue. 13, p. 1723.
Bach, Jean-François and Perez-Arroyo, Alicia 2014. The Autoimmune Diseases.
Correale, Jorge 2014. Helminth/Parasite Treatment of Multiple Sclerosis. Current Treatment Options in Neurology, Vol. 16, Issue. 6,
Ebner, F. Hepworth, M. R. Rausch, S. Janek, K. Niewienda, A. Kühl, A. Henklein, P. Lucius, R. Hamelmann, E. and Hartmann, S. 2014. Therapeutic potential of larval excretory/secretory proteins of the pig whipwormTrichuris suisin allergic disease. Allergy, Vol. 69, Issue. 11, p. 1489.
Heylen, Marthe Ruyssers, Nathalie E. Gielis, Els M. Vanhomwegen, Els Pelckmans, Paul A. Moreels, Tom G. De Man, Joris G. and De Winter, Benedicte Y. 2014. Of worms, mice and man: An overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacology & Therapeutics, Vol. 143, Issue. 2, p. 153.
Lin, Chen Hsing Kadakia, S. and Frieri, Marianne 2014. New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease. Autoimmunity Reviews, Vol. 13, Issue. 2, p. 114.
Nascimento, Wheverton C. Silva, Roeckson P. Fernandes, Erica S. Silva, Maria C. Holanda, Gabriela C. Santos, Patrícia A. Albuquerque, Mônica P. Costa, Vlaudia A. Pontes-Filho, Nicodemos T. and Souza, Valdênia O. 2014. Immunomodulation of liver injury by Ascaris suum extract in an experimental model of autoimmune hepatitis. Parasitology Research, Vol. 113, Issue. 9, p. 3309.
Fleming, J.O. 2013. Helminth therapy and multiple sclerosis. International Journal for Parasitology, Vol. 43, Issue. 3-4, p. 259.
McSorley, Henry J. Hewitson, James P. and Maizels, Rick M. 2013. Immunomodulation by helminth parasites: Defining mechanisms and mediators. International Journal for Parasitology, Vol. 43, Issue. 3-4, p. 301.
Peón, Alberto N. Espinoza-Jiménez, Arlett and Terrazas, Luis I. 2013. Immunoregulation byTaenia crassicepsand Its Antigens. BioMed Research International, Vol. 2013, p. 1.
Initial clinical trials using Trichuris suis eggs (TSO) in autoimmune diseases such as inflammatory bowel disease, revealed a striking suppressive effect on the autoimmune response. Here, we analysed the effect of TSO therapy on the course of multiple sclerosis (MS), as a Th1/Th17-associated autoimmune disease. Different immunological parameters in four patients with secondary progressive MS were surveyed during a 6-month therapy with TSO, focusing on the modulation of T-cell Th1–Th2 balance as well as on the innate immune response. We are able to show a slight downregulation of the Th1-associated cytokine pattern, especially relevant in interleukin (IL)-2 (P < 0.05 after 2 months of therapy), with a temporary increase of Th2-associated cytokines such as IL-4. Furthermore, mild eosinophily and changes in CD4+ and CD8+T cells and natural killer (NK) CD56 bright cell numbers were observed. The findings observed in this group of patients suggest that TSO therapy has a moderate immunomodulatory impact in MS.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.